Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial
Open accessThe DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index; 6 of the 11 sources its claims cite were checked for support.
Abstract
Phase II randomized trial of perioperative propranolol and etodolac in pancreatic cancer surgery.
Overview
CoChat Summary
TL;DR
The PROSPER phase II randomized, placebo-controlled trial tested perioperative propranolol plus etodolac around partial pancreatoduodenectomy for pancreatic cancer. It found no safety concerns, but the intervention was not feasible because recruitment was slow and adherence was limited.
Key findings
- The trial was prematurely closed after screening 1026 patients; 26 were randomized, 20 received trial medication at least once, and only 9 received verum vs. 11 placebo in the final safety set.
- Safety was acceptable: there were 0 serious adverse reactions and 20 serious adverse events total, with 6 in the treatment group and 14 in the placebo group; the SAE rate was 2.095 times as high in placebo as verum (95%-CI 0.805–5.45; p = 0.1297).
- Feasibility was poor: adherence was lower in the verum group, with etodolac adherence 50% ± 26% vs. 78% ± 29% in placebo (p = 0.06) and propranolol adherence 47% ± 28% vs. 69% ± 37% (p = 0.20).
- Preliminary efficacy signals were favorable but exploratory: median DFS was 16.36 months in verum vs. 11.25 months in placebo, and distant recurrence was 11.1% vs. 54.5%, respectively.
- In translational analyses, verum was associated with a trend toward faster postoperative IL-6 normalization and less loss of immune effectors, while no circulating tumor cells were detected in either group.
Methods
- Randomized, patient- and observer-blinded, placebo-controlled, phase II trial at Heidelberg University Hospital in patients undergoing partial pancreatoduodenectomy for pancreatic cancer.
- Patients were randomized 1:1 to perioperative propranolol + etodolac or matching placebo; the planned sample was 100 randomized patients, but the trial stopped early for slow recruitment.
- Main analyses were exploratory in the safety set; primary safety outcome was SAE rate, primary feasibility outcome was adherence, with OS, DFS, recurrence, morbidity, and translational immune measures also assessed.
Limitations
- Stated in the paper: the trial stopped early because of slow recruitment, adherence was limited, the cohort was heterogeneous by diagnosis/stage, and only the combination therapy was tested rather than monotherapy.
- Stated in the paper: translational analyses were incomplete because of shortcomings in specimen sampling and quality.
- Evident from the text: the final analyzed sample was very small, so all efficacy and translational findings are underpowered and exploratory.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 61 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A combined treatment with betablockers and cyclooxygenase inhibitors (COX-inhibitors) in terms of drug repurposing promises an easy and effective approach to mitigate these effects [8].”
§ Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial > Background
What the sources say
- Partly supportedcites [8] Ricon I et al (2019) Perioperative biobehavioral interventions to prevent cancer recurrence through combined inhibition of beta-adrenergic and cyclooxygenase 2 signaling. Cancer 125(1):45–56 sourceExperimental — accuracy not yet measured
The section on perioperative clinical studies reports that combined propranolol and etodolac improved biological markers and may reduce metastatic effects. It also says the clinical trials were small, the colorectal cancer disease-free survival improvement was not statistically significant, and safety precautions are needed. Thus the paper supports the approach as promising, but not as an established easy and effective way to mitigate those effects. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These findings further corroborate preclinical studies by the same group that the combined treatment with propranolol and etodolac may reduce metastases [23, 24].”
§ Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial > Discussion
What the sources say
- Not checked — no full text of the sourcecites [23] Benish M et al (2008) Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 15(7):2042–2052 source
- Supportedcites [24] Sorski L et al (2016) Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through beta-adrenoceptors blockade and COX2 inhibition. Brain Behav Immun 58:91–98 source
Section 3.1.2 reports that combined propranolol and etodolac significantly reduced surface hepatic metastases in mice, whereas either drug alone did not. This directly supports the claim about preclinical studies; the supplied passages do not provide page numbers. (LLM, conf=0.94)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The resulting physiological changes can create a protumorigenic or prometastatic environment, potentially facilitating cancer progression or recurrence [7].”
§ Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial > Background
What the sources say
- Supportedcites [7] Horowitz M et al (2015) Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol 12(4):213–226 source
The Introduction explains that perioperative changes can act on residual malignant cells, suppress antimetastatic immunity, and alter their microenvironment, potentially enabling metastases to develop. The ‘Perioperative physiological responses’ section likewise says these responses can substantially affect the metastatic process. This supports the claim’s cautious wording. (LLM, conf=0.94)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, they demonstrated in a cohort of 631 PDAC patients that the intake of a non-selective betablocker, such as propranolol, led to an improved overall survival compared to patients without betablocker therapy (40 vs. 23 months median overall survival) [25].”
§ Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial > Discussion
What the sources say
- Partly supportedcites [25] Renz BW et al (2018) beta2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell 33(1):75-90.e7 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
boostedstates a causen = 631- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Other pancreas-specific complications did not show notable differences.”
§ Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 72 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 31
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329 · cited 1×
“The current report was prepared in accordance with the recommendations of the CONSORT statement [11].”
Bassi, C., Marchegiani, G., Dervenis, C., Sarr, M., Abu Hilal, M., Adham, M., Allen, P., Andersson, R., Asbun, H. J., Besselink, M. G., et al. (2017) · Surgery · doi:10.1016/j.surg.2016.11.014 · Cited by 4,276 · cited 1×
“Furthermore, 30-and 90-day mortality, pancreas-associated morbidity including postoperative pancreatic fistula [13], delayed gastric emptying [14] and postpancreatectomy hemorrhage [15] according to the respective ISGPS definitions, postoperative biliary leakage according to the ISGLS definition…”
Self-citationWente, M. N., Bassi, C., Dervenis, C., Fingerhut, A., Gouma, D. J., Izbicki, J. R., Neoptolemos, J. P., Padbury, R. T., Sarr, M. G., Traverso, L. W., et al. (2007) · Surgery · doi:10.1016/j.surg.2007.05.005 · Cited by 3,053 · cited 1×
“Furthermore, 30-and 90-day mortality, pancreas-associated morbidity including postoperative pancreatic fistula [13], delayed gastric emptying [14] and postpancreatectomy hemorrhage [15] according to the respective ISGPS definitions, postoperative biliary leakage according to the ISGLS definition…”
Self-citationFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Wente, M. N., Veit, J. A., Bassi, C., Dervenis, C., Fingerhut, A., Gouma, D. J., Izbicki, J. R., Neoptolemos, J. P., Padbury, R. T., Sarr, M. G., et al. (2007) · Surgery · doi:10.1016/j.surg.2007.02.001 · Cited by 2,616 · cited 1×
“…pancreas-associated morbidity including postoperative pancreatic fistula [13], delayed gastric emptying [14] and postpancreatectomy hemorrhage [15] according to the respective ISGPS definitions, postoperative biliary leakage according to the ISGLS definition [16] and post-operative…”
Self-citationKamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Koch, M., Garden, O. J., Padbury, R., Rahbari, N. N., Adam, R., Capussotti, L., Fan, S. T., Yokoyama, Y., Crawford, M., Makuuchi, M., et al. (2011) · Surgery · doi:10.1016/j.surg.2010.12.002 · Cited by 2,001 · cited 1×
“…pancreatic fistula [13], delayed gastric emptying [14] and postpancreatectomy hemorrhage [15] according to the respective ISGPS definitions, postoperative biliary leakage according to the ISGLS definition [16] and post-operative intra-abdominal fluid collection or abscess were assessed.”
Self-citationERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
Dumonceau, J.-M., Kapral, C., Aabakken, L., Papanikolaou, I. S., Tringali, A., Vanbiervliet, G., Beyna, T., Dinis-Ribeiro, M., Hritz, I., Mariani, A., et al. (2020) · Endoscopy · doi:10.1055/a-1075-4080 · Cited by 934 · cited 1×
“The underlying mechanisms could be similar to the ones of NSAIDs in the prevention of post-ERCP pancreatitis, which is even recommended by current guidelines [21].”
Cited by
Peripheral Nerves in Cancer: Regulatory Roles and Therapeutic Strategies
Fu, Y., Ge, Z., Cao, Q., Li, Z., Zhang, A., Zhu, H., & Teng, G. (2026) · MedComm · doi:10.1002/mco2.70594 · Cited by 10
Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions
Nagaraju, G. P., Nellipudi, H. R., Ganji, C., Kuppala, V., Ganji, S. P., Kumari, S., Farran, B., Srilatha, M., Guenter, R. E., & El‐Rayes, B. F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02705-5 · Cited by 9
“187 A multicohort transcriptomic analysis investigated that T-cell subpopulations reshape the TME and in fl uence immunotherapy in PDAC.”
Neuro-tumor-immune crosstalk in pancreatic cancer: Mechanisms and therapeutic insights
Jin, J., He, B., Wang, X., Zhang, Y., You, H., Mo, S., Guo, D., & Shi, S. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189575 · Cited by 5
Redefining surgical oncology: active immune microenvironment modulation beyond tumor resection
谭家雄, Zhang, Y., Wang, J., Xia, Y., Pan, Y., & Zhao, Q. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116521 · Cited by 3
Sakis, N., Sorski, L., Asraf, E., Ricon‐Becker, I., Shaashua, L., Haldar, R., Shvalbo, B. B., Shabat-Simon, M., Gutman, M., Nissan, A., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1823113 · Cited by 6
“Importantly, a recent RCT in PC patients (the PROSPER trial) tested a nearly identical perioperative regimen and found no safety concerns (Hüttner et al., 2025).”
Metadata
- Authors
- Hüttner, F. J., Klotz, R., Giese, N. A., Kong, B., Ahmed, A., Merz, D., Pöchmann, A., Burghaus, I., Hackert, T., Strobel, O., Mihaljevic, A. L., Michalski, C. W., Büchler, M. W., & Diener, M. K.
- Affiliations
- University Hospital Heidelberg (DE)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Champalimaud Foundation (PT)
- Corresponding author
- Diener, Markus K.
- ORCID
- Venue
- Langenbeck's Archives of Surgery
- Published
- 2025-05-22
- Volume
- 410
- Issue
- 1
- Pages
- 168-168
- ISSN
- 0023-8236 (ISSN-L)
- 1435-2451
- PMC
- PMC12098435
- OpenAlex
- W4410602717
- Cited by
- 15
- References
- 25
- Citations by year
- 2026: 14 · 2025: 1
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Langenbeck s Archives of Surgery (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Anticancer Fund (A56)
- Universitätsklinikum Heidelberg
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
- Keywords
- pancreatic cancer, propranolol, etodolac, partial pancreatoduodenectomy, beta-blockers, COX-2 inhibitors, disease-free survival, recurrence, medication adherence, serious adverse events, translational research
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Propranolol, Pancreaticoduodenectomy, Etodolac, Perioperative Care, Cyclooxygenase 2 Inhibitors, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial. https://app.cochat.ai/papers/10.1007/s00423-025-03735-3
- The paper
- Hüttner, F. J., Klotz, R., Giese, N. A., Kong, B., Ahmed, A., Merz, D., Pöchmann, A., Burghaus, I., Hackert, T., Strobel, O., Mihaljevic, A. L., Michalski, C. W., Büchler, M. W., & Diener, M. K. (2025). Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial. Langenbeck's Archives of Surgery. https://doi.org/10.1007/s00423-025-03735-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.